Your browser does not support JavaScript!
:::
游佳融

游佳融 (Chia-Jung Yu)

職稱:副教授

研究室名稱:功能性蛋白質體實驗室

最高學歷Ph. D.

學校/國家:國立台灣大學/台灣

分機號碼3424

電子郵件帳號yucj1124@mail.cgu.edu.tw

個人網頁網址:https://d000003200.wixsite.com/yu-cj

研究室現有

博士班研究生2

碩士班研究生 5

專任研究助理 2

大學部專題生1

Update 2017/05/10

研究方向及研究室特色:

壹、肺癌標誌蛋白質的開發與功能性探討

肺癌是台灣也是全世界最主要的癌症死亡原因,其中非小細胞肺癌是屬於高發生率與高致死率的癌症。我們實驗室致力於發展有助於非小細胞肺癌診斷/預後與治療的腫瘤標誌(tumor marker) 蛋白質。此外,我們也進一步探討關鍵腫瘤標誌蛋白質的分子作用機轉,期待能為肺癌找尋新的治療方向。我們運用的材料包含肺癌組織,體液 (血清,肋膜積液) 以及肺癌細胞株。主題包括: ()建立與腫瘤分期相關的組織蛋白體資料庫以尋找與轉移相關的蛋白質,用以評估肺癌病人的預後與治療 ()發展體液中,有助於非小細胞肺癌診斷/預後的腫瘤標 ()深入探討肺腺癌標誌蛋白質的分子作用機轉,其中專注於 KPNA2 這個具有發展潛力的致癌分子的一系列研究,包含 (a). 研究 KPNA2 蛋白質在肺腺癌細胞中的訊息聯絡網 (b). 分析與腫瘤侵犯力有關的 KPNA2蛋白質複合體成員及其作用機轉 (c). 找尋調節KPNA2 在癌症細胞過度表現的訊息傳遞路徑與轉錄因子,以協助肺癌標靶治療的開發

 

貳、探討人類 Arl1 蛋白質複合體及其生理功能

腺嘌呤核苷二磷酸核糖化相似因子 (Arf-like; Arl) Ras small GTPase 超級家族的成員。Arl1 主要位於反式高基氏體網路上,藉由調節其作用分子 (effector)參與細胞內的囊泡運輸 (vesicle transport)。然,關於 Arl1 及其 effector 的詳細分子作用機轉與扮演的生理功能則尚未釐清。我們利用蛋白質體學方法系統性的鑑定 Arl1 蛋白質複合體成員並驗證 Arl1 與其作用分子 (effector) 共同參與囊泡運輸的分子機轉並探討 Arl1 及其作用分子生理意義。

 

最近五年所發表論文: (*, Corresponding author)

1.        Tsai CH, Chen YJ, Yu CJ, Tzeng SR, Wu IC, Kuo WH, Lin MC, Chan NL, Wu KJ, Teng SC. SMYD3-Mediated H2A.Z.1 Methylation Promotes Cell Cycle and Cancer Proliferation. Cancer Res. 2016 Aug 28. pii: canres.0500.2016. [PubMed]

2.        Hsu CH, Hsu CW, Hsueh C, Wang CL, Wu YC, Wu CC, Liu CC, Yu JS, Chang YS, Yu CJ*. Identification and characterization of potential biomarkers by quantitative tissue proteomics of primary lung adenocarcinoma. Mol. Cell. Proteomics 2016 Jul;15(7):2396-410 .[PubMed]

3.        Wang CI, ChenYY, Wang CL, Yu JS, Chang YS, Yu CJ*. mTOR regulates proteasomal degradation and Dp1/E2F1-mediated transcription of KPNA2 in lung cancer cells. Oncotarget 2016 May 3;7(18):25432-42. [PubMed]

4.        Hsu JW, Tang PH, Wang IH, Liu CL, Chen WH, Tsai PC, Chen KY, Chen KJ, Yu CJ, Lee FJ*. Unfolded protein response regulates yeast Arl1p activation at late Golgi via phosphorylation of Arf GEF Syt1p. Proc. Natl. Acad. Sci. U S A., 2016 Mar 22;113(12):E1683-90. [PubMed]

5.        Shih CL, Chong KY, Hsu SC, Chien HJ, Ma CT, Chang JW, Yu CJ*, Chiou CC*. Development of a magnetic bead-based method for the collection of circulating extracellular vesicles. N. Biotechnol. 2016 Jan 25;33(1):116-22. 

6.        Liu PJ, Chen C, Wang CL, Wu YC, Hsu CW, Lee CW, Huang LH, Yu JS, Chang YS, Wu CC*, Yu CJ*.In-depth proteomic analysis of six types of exudative pleural effusions for non-small cell lung cancer biomarker discovery.  Mol. Cell. Proteomics 2015 Apr;14(4):917-32. [PubMed]

7.        Wang CI, Wang CL, Wu YC, Feng HP, Liu PJ, Chang YS, Yu JS, Yu CJ*. Quantitative proteomics reveals a novel role of karyopherin alpha 2 (KPNA2) in cell migration through the regulation of vimentin-pErk protein complex levels in lung cancer. J. Proteome Res.  2015 Apr 3;14(4):1739-51. [PubMed]

8.        Lee CW, Chang KP, Chen YY, Liang Y, Hsueh C, Yu JS, Chang YS, Yu CJ*. Overexpressed tryptophanyl-tRNA synthetase, an angiostatic protein, enhances oral cancer cell invasiveness. Oncotarget 2015 Sep 8;6(26):21979-92.  [PubMed]

9.        Huang LH, Lee WC, You ST, Cheng CC, Yu CJ*. Arfaptin-1 negatively regulates Arl1-mediated retrograde transport. PLoS One 2015 Mar 19;10(3):e0118743. [PubMed]

10.    Shih CL, Luo JD, Chang JW, Chen TL, Chien YT, Yu CJ*, Chiou CC*. Circulating messenger RNA profiling with microarray and next-generation sequencing: cross-platform comparison. Cancer Genomics Proteomics 2015 09-10;12(5):223-230. [PubMed]

11.    Yu CJ*, Ko CJ, Hsieh CH, Chien CT, Huang LH, Lee CW, Jiang CC*. Proteomic analysis of osteoarthritic chondrocyte reveals the hyaluronic acid-regulated proteins involved in chondroprotective effect under oxidative stress. J. Proteomics 2014 Mar 17;99:40-53. [PubMed] 

12.    Chang SW, Fann CS, Su WH, Wang YC, Weng CC, Yu CJ, Hsu CL, Hsieh AR, Chien RN, Chu CM, Tai DI*. A genome-wide association study on chronic HBV infection and its clinical progression in male Han-Taiwanese. PLoS One 2014 Jun 18;9(6):e99724. [PubMed]

13.    Chen CD, Wang CL, Yu CJ, Chien KY, Chen YT, Chen MC, Chang YS, Wu CC, Yu JS. Targeted proteomics pipeline reveals potential biomarkers for the diagnosis of metastatic lung cancer in pleural effusion. J Proteome Res. 2014 Jun 6;13(6):2818-29. [PubMed]

14.    Wang CI, Chien KY, Wang CL, Chang YS, Yu JS, Yu CJ*. Quantitative proteomics reveals regulation of KPNA2 and its potential novel cargo protein in non-small cell lung cancer. Mol. Cell. Proteomics 2012 Nov;11(11):1105-22. [PubMed]

15.    Yu CJ*, Wang CL, Wang CI, Chen CD, Dan YM, Wu CC, Wu YC, Lee IN, Tsai YH, Chang YS, Yu JS. Comprehensive proteome analysis of malignant pleural effusion for lung cancer biomarker discovery by using multidimensional protein identification technology. J. Proteome Res. 2011 Oct 7;10(10):4671-82. [PubMed]

16.    Yu CJ, Chang KP, Chang YJ, Hsu CW, Liang Y, Yu JS, Chi LM, Chang YS, Wu CC*. Identification of guanylate-binding protein 1 as a potential oral cancer marker involved in cell invasion using Omics-based analysis. J. Proteome Res. 2011 Aug 5;10(8):3778-88. [PubMed]

17.    Wang CI, Wang CL, Wang CW, Chen CD, Wu CC, Tsai YH, Chang YS, Yu JS, Yu CJ*.  Importin subunit alpha-2 is identified as a potential biomarker for non-small cell lung cancer by integration of the cancer cell secretome and tissue transcriptome. Int. J. Cancer. 2011 May 15;128(10):2364-72. [PubMed]

 

 

瀏覽數  
  • 友善列印
  • 新增到收藏夾
  • 分享
將此文章推薦給親友
請輸入此驗證碼
Voice Play
更換驗證碼